Background:
Human immunity to Monkeypox infection (Mpox) has not been extensively characterized in people with HIV (PWH). Here, we analyzed antibody responses in outpatients diagnosed with Mpox during the 2022 outbreak in Barcelona, Spain who had been enrolled in the MoViE study (NCT05476744, Suñer et al 2022)
Methods:
Observational, prospective, multicentre study designed to evaluate time from symptom onset (SO) to viral DNA clearance. A severity score was generated based on the number of local and distal skin lesions and presence of systemic symptoms. Samples from multiple body sites were collected at diagnosis and weekly for one month. Blood was collected from an immune subset of 33 individuals at Mpox diagnosis, 1, 3 and 6 months. IgG and IgA titers in plasma were determined by ELISA against recombinant Mpox proteins A35, Envelope H3 and A29.
Results:
All participants were male aged 25 to 58 years. Participants were diagnosed at a median of 5 days (range 1-10) since SO and had mild/moderate disease. Fourteen (42%) were PWH, with last CD4+ T cells >450/µL and all but 3 were ART-suppressed. Mpox clinical severity was similar between PWH and HIV negative individuals (HIVneg). At Mpox diagnosis, no differences in the breadth of reactivity or IgG titers to A35, H3 and A29 proteins were detected between PWH and HIVneg. IgGs to at least one Mpox antigen were detected in 11/13 PWH and 17/19 HIVneg. Anti-A35 IgGs in participants aged >48 years were significantly higher than in younger participants (p=0.01) suggesting potential pre-existing immunity due to previous smallpox vaccination, consistent with the time when immunizations were globally ceased. Despite anti-A35/H3/A29 IgGs did not correlate with days since SO or Mpox DNA levels in skin lesions or blood, higher titers of anti-A35/A-29 IgG were associated with a lower severity score (Rho -0,43 and -0.40 respectively, p< 0.05). Moreover, anti-A35/H3 IgG and IgA correlated with less days to negativization of viral DNA in skin lesions and higher DNA copies cleared per day. Longitudinal analysis at 1, 3 and 6 months after diagnosis, as well as viral neutralization and T-cell assays are ongoing at the time of submission.
Conclusions:
In our cohort, PWH with CD4+ >450/µL had a similar clinical presentation of Mpox to HIVneg individuals. Magnitude of humoral immune responses at the time of diagnosis was associated with a milder presentation and a shorter and faster viral clearance of Mpox DNA in skin lesions. These results may inform isolation strategies.